-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[June 1, 2021 / List of medical information] On June 1, the CDE website opened the "Children's Medication Column"; a case of human infection with H10N3 avian influenza was found in Jiangsu; Pan Guangcheng resigned as independent director of Calais.
[June 1, 2021/Medical Information List] Daily news of fresh medicines and medical news, speed reading and follow you together!
Part 1 Policy Brief
Part 1 Policy Briefing Part 1 Policy BriefingThe State Food and Drug Administration issued an announcement on the addition of relevant information in the instructions of haloperidol tablets
The State Food and Drug Administration issued an announcement on the addition of relevant information in the instructions of haloperidol tabletsOn May 31, the State Food and Drug Administration issued an announcement regarding the addition of drug information to children in the instructions of haloperidol tablets and other varieties.
On June 1st, CDE website opened "Children's Medication Column"
On June 1st, CDE website opened "Children's Medication Column"On May 31, the Drug Evaluation Center of the State Food and Drug Administration announced the opening of the "Children's Drug Column" on June 1, and will centrally disclose policies, regulations, guidelines, and training materials related to children's drug use.
The State Food and Drug Administration issued an announcement on the implementation of the "Regulations on the Supervision and Administration of Medical Devices" and other matters
The State Food and Drug Administration issued an announcement on the implementation of the "Regulations on the Supervision and Administration of Medical Devices" and other mattersOn May 31, the State Food and Drug Administration issued an announcement on the implementation of the "Regulations on the Supervision and Administration of Medical Devices" and other matters.
The notice on the full implementation of the new drug information application for drug listing and open bargaining procurement
The notice on the full implementation of the new drug information application for drug listing and open bargaining procurementOn May 31, Shanghai Sunshine Pharmaceutical Purchasing Network released the information publicity (the thirteenth batch) of new drug applications for the full implementation of open drug bargaining procurement on the Internet.
11 new local confirmed cases in Guangdong
11 new local confirmed cases in GuangdongOn June 1, the Guangdong Provincial Health Commission notified that from 0-24 on May 31, Guangdong added 11 local confirmed cases (including 1 case of asymptomatic infection transferred to be diagnosed), and 2 additional local asymptomatic infections By.
A case of human infection with H10N3 avian influenza detected in Jiangsu
A case of human infection with H10N3 avian influenza detected in JiangsuThe National Health Commission notified on June 1 that a human case of H10N3 avian influenza has been detected in Jiangsu Province.
Part 2 Observation of Sankei
Part 2 Sankei Observation Part 2 Sankei ObservationPan Guangcheng resigned as independent director of Kailai Ying
Pan Guangcheng resigned as independent director of Kailai YingOn June 1, Kailaiying issued an announcement stating that it had recently received a written resignation report from independent director Pan Guangcheng.
The CEO and CFO of Hanhui Pharmaceutical have changed
The CEO and CFO of Hanhui Pharmaceutical have changedOn May 31, Hanhui Pharmaceutical announced major organizational restructuring and personnel appointments.
Chuangxiang Bio announced the completion of US$100 million Series C financing
Chuangxiang Bio announced the completion of US$100 million Series C financingChuangxiang Biotech today announced the completion of a US$100 million Series C financing, jointly led by Honghui Capital and existing shareholder Ruifu Medical Venture Capital Fund, new investors such as Dingpei Asset Management, Qianhai Qinzhi, and other existing shareholders Zhongnan Venture Capital, Kunlun Capital, etc.
Chuanxin Biotechnology completes nearly 100 million yuan in angel round financing
Chuanxin Biotechnology completes nearly 100 million yuan in angel round financingOn June 1, Chuanxin Biotechnology announced the completion of an angel round of financing of nearly 100 million yuan.
Cinda Biotech obtains exclusive license for ROS1/NTRK inhibitors from Biochem
Cinda Biotech obtains exclusive license for ROS1/NTRK inhibitors from BiochemOn June 1, Baoyuan Pharmaceutical and Cinda Biotech announced that they had reached an agreement under which Baoyuan Pharmaceutical authorized Cinda Biotech as the exclusive partner to jointly develop and commercialize Baoyuan Biopharmaceuticals in the Greater China Region (including Mainland China, Hong Kong, Macau and Taiwan).
Part 3 Drug News
Part 3 Drug News Part 3 Drug News InformationAbbVie's JAK Inhibitor Key Global Phase 3 Results Announced for Treatment of Atopic Dermatitis
AbbVie's JAK Inhibitor Key Global Phase 3 Results Announced for Treatment of Atopic DermatitisRecently, AbbVie announced that the "Lancet" magazine published a key global phase 3 clinical study of its JAK inhibitor upatinib for moderate to severe atopic dermatitis-Measure Up 1, Measure Up 2 and AD Up The main analysis results.
NICE approves Johnson & Johnson Tremfya to treat active psoriatic arthritis
NICE approves Johnson & Johnson Tremfya to treat active psoriatic arthritisA few days ago, Johnson & Johnson Xi’an Janssen IL-23 inhibitor Tremfya has been included in the NHS of the British healthcare system by the National Institute of Health and Care Excellence for the treatment of active psoriatic arthritis.
Wanchun Pharmaceutical's Pranabrin listing application obtains priority review by the U.
Wanchun Pharmaceutical's Pranabrin listing application obtains priority review by the U.
FDA restricts obeticholic acid for PBC patients with advanced liver cirrhosis
FDA restricts obeticholic acid for PBC patients with advanced liver cirrhosis
Recently, the U.
S.
FDA has restricted the use of Intercept Pharmaceuticals' liver disease drug Ocaliva because an investigation found that Ocaliva is associated with severe liver damage (including liver failure) in certain patients.
Currently, Ocaliva's prescription information in the United States has been updated.
(Sina Pharmaceutical News)
Privatrol Pharma gets approval for generic bivalrudine for injection
Privatrol Pharma gets approval for generic bivalrudine for injection
On May 31, Puli Pharmaceuticals issued an announcement stating that the company had recently received a notice of approval for the marketing of a generic bivalrudine for injection from the FDA.
It is reported that bivalrudine for injection is a synthetic anticoagulant drug.
(Puli Pharmaceutical Announcement)
Zuoli Pharmaceutical: Esomeprazole Sodium for Injection Obtained Drug Registration Approval
Zuoli Pharmaceutical: Esomeprazole Sodium for Injection Obtained Drug Registration Approval
On June 1, Zuoli Pharmaceutical announced that the company has recently received the "Drug Registration Certificate" for Esomeprazole Sodium for Injection approved and issued by the National Medical Products Administration.
The drug has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog" (2020 Edition) Class B drugs.
The applicable symptoms include: as an alternative therapy for gastroesophageal reflux disease when oral therapy is not applicable.
(Announcement from Zuoli Pharmaceutical)
Xianju Pharmaceutical: Ropivacaine Hydrochloride Injection passed the consistency evaluation
Xianju Pharmaceutical: Ropivacaine Hydrochloride Injection passed the consistency evaluation
On June 1, Xianju Pharmaceutical announced that the company's ropivacaine hydrochloride injection passed the quality and efficacy consistency evaluation of generic drugs.
It is reported that the drug is clinically suitable for surgical anesthesia and acute pain control.
(Announcement of Xianju Pharmaceutical)
10 Chinese products are shortlisted in the British Ministry of Health's new crown antigen reagent list
10 Chinese products are shortlisted in the British Ministry of Health's new crown antigen reagent list
A few days ago, the British Ministry of Health website has updated the "List of Validated New Coronary Antigen Kit Products".
The updated list shows that 24 new coronavirus antigen reagents have passed the verification, 10 of which are manufactured by Chinese companies, including Oriental Bio, Deep Blue Medical, Products from Delanos, Shuoshi Biology, Aikang Biology, Jidan Biology, etc.
Among them, Oriental Biological products are used in British schools instead of lnnova.
According to the British "Schoolsnet" network, from May 10, "NHS Testing and Tracking" has launched Oriental Bio's new crown antigen detection reagents for on-site asymptomatic testing sites in schools and universities.
(Associated Finance Press)
